What is ImmunoPulse?

Many cancer research and treatment companies create and utilize various methods of treatment. These may be a combination of existing techniques or a new technology developed by the company itself. At OncoSec, one of our treatment methods is ImmunoPulse: a system we’re testing for the treatment of late-stage skin cancer, including merkel cell carcinoma, cutaneous T-cell lymphoma, and metastatic melanoma. With pending announcements surrounding interim data from our phase II trial for metastatic melanoma coming up soon, we would like to review a bit of the description of our ImmunoPulse treatment option currently being tested.

ImmunoPulse is a proposed immunotherapy treatment option that potentially stimulates the body’s immune system, to fight the cancer. Opposed to traditional methods that work by introducing poisonous chemicals into the body to fight the disease,the idea behind immunotherapy is to trigger the body to do most of the work. This could be argued to be more of a holistic approach that may offer much health advantages compared to radiation and chemotherapy, which cab both be quite debilitating.

Our ImmunoPulse program is a type of immunotherapy meant to deliver instructions directly into the patients’ cells. These instructions cause the cells to begin producing and secreting naturally occurring IL-12 proteins: a key component for identifying, locating and destroying cancerous cells. This makes the immune system the most important part of cancer treatment, allowing for a less invasive treatment regiment that causes less toxic harm to the body. This style of novel treatment that uses gene therapy may offer many other functions, outside of localized tumors, including helping to fight cancerous lesions at remote parts of the body.


OncoSec Medical System
The OncoSec Medical System (OMS) uses electroporation, to allow gene instructions to be passed directly into cells.


OMS system: an electroporation system that uses electricity, in order to aid in the delivery of treatment into the body. After the DNA IL-12 proteins are injected, the OMS system is administered, in order to give the treatment a channel into the patients’ cells. This style of administering treatment creates an electric field that stimulates cells and allows our treatment agent to pass right into them. This less invasive method is meant to cause a lower number of side effects to patients, when compared to methods such as chemotherapy and radiation therapy.

We are also currently undergoing testing this treatment type along with other methods, to create combined therapy techniques, alongside Old Dominion University and the Frank Reidy Research Center for Bioelectrics. We will continue to study new and progressive cancer treatment options, in order to discover safer, more effective methods for treating late-stage skin cancers. With the last update regarding the analysis of the interim results for our phase II melanoma tests, we are confident in pursuing this type of treatment. More updates surrounding these results will follow, over the coming weeks.

To receive updates and press releases from OncoSec, please subscribe to our newsletter at the bottom of the page. For cancer prevention tips, risk factors and other industry news, please join our Facebook and Twitter communities.